<DOC>
	<DOCNO>NCT01483534</DOCNO>
	<brief_summary>The purpose study evaluate safety Targeted Lung Denervation Therapy ( TLD TherapyTM ) patient suffer COPD . Technical feasibility IPS SystemTM also evaluate confirmation successful application TLD Therapy .</brief_summary>
	<brief_title>Innovative Pulmonary Solutions ( IPS ) System Targeted Lung Denervation</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>FEV1 30 % 60 % FEV1/FVC &lt; 70 % Prior smoker ( least 10 pack year ) Quit smoke least 6 month Pulmonary hypertension , peripheral edema suggest CHF polycythemia Prior lung transplant , LVR , LVRS , median sternotomy , bullectomy lobectomy Pulmonary nodule require surgery Presence implantable electronic device Active respiratory infection within recent week COPD exacerbation within recent week Recent Myocardial infarction ( MI ) Recent unstable life threaten arrhythmia Malignancy treat radiation chemotherapy within last 2 year Presence clinical diagnosis respiratory disease COPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Intervention</keyword>
	<keyword>Device</keyword>
	<keyword>Denervation</keyword>
	<keyword>Lung</keyword>
	<keyword>Holaira , Inc .</keyword>
	<keyword>Innovative Pulmonary Solutions , Inc .</keyword>
</DOC>